Results 51 to 60 of about 461 (125)

Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants

Diabetes, Obesity and Metabolism
Abstract Aims The combination of cagrilintide and semaglutide (CagriSema) is being developed for the treatment of obesity and type 2 diabetes. The objective of this thorough QT study was to confirm that cagrilintide does not result in a clinically relevant prolongation in cardiac repolarization
Maria B. N. Gabe, Rainard Fuhr, Angela Sinn, Astrid Eliasen, Kasper K. Berthelsen, Anja B. Kuhlman, Tine A. Bækdal, Ayna B. Nejad   +7 more
openaire   +2 more sources

A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies

Journal of Obesity, Volume 2026, Issue 1, 2026.
Background Obesity is a chronic, multifactorial disease associated with significant cardiometabolic, psychological, and socioeconomic consequences. Its complex etiology necessitates integrated, evidence‐based management strategies beyond simple caloric restriction.
Iman Saad Ahmed, Sara Luay Tapponi, Hala Malek Manaa, Amina Soltani, Elzahraa Shehata Hussein, Fatemeh Ali Parvaresh, Zahid Hussain, Jasbir Arora (RSS)   +7 more
wiley   +1 more source

Recent advances in peptide-based therapies for obesity and type 2 diabetes [PDF]

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies.
Flatt, Peter R, Conlon, J Michael, Bailey, Clifford J   +2 more
core   +1 more source

The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies

Obesity Reviews, Volume 26, Issue 12, December 2025.
ABSTRACT Obesity is a chronic metabolic disease characterized by disturbances in energy homeostasis, leading to excessive fat accumulation. The pathogenesis of the disease is shaped by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.
Gašper Tonin, Stjepan Eržen, Zala Mlinarič, Dubravka Jurišić Eržen, Simon Horvat, Tanja Kunej, Jasna Klen   +6 more
wiley   +1 more source

Advancements in the management of obesity: a review of current evidence and emerging therapies [PDF]

Introduction: Obesity is the modern world’s current epidemic, with substantial health and economic impact. This study aimed to provide a narrative overview of the past, currently available, and future treatment options that offer therapeutic and ...
Abdalla Ahmed, Mohammed Altigani, Ssemmondo, Emmanuel, Sathyapalan, Thozhukat, Mark-Wagstaff, Charlotte   +3 more
core   +1 more source

Updated MD trajectories and topology files for "Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors" - Nature Communications [PDF]

Molecular dynamics trajectories (3 separated replicas, stripped of POPC, water and NaCl) for Cagri:AMY3R:Gs and rAMY:AMY3R:Gs. The topology file for GC9 and missing parameters (i.e. not present in the standard CHARMM36 force field) are provided.
Deganutti, Giuseppe; id_orcid, Coventry University   +1 more
core   +1 more source

A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide’s Effects on Energy Balance

Abstract Amylin analogs, including potential anti-obesity therapies like cagrilintide, act on neurons in the brainstem dorsal vagal complex (DVC) that express calcitonin receptors (CALCR). These receptors, often combined with receptor activity-modifying proteins (RAMPs), mediate the suppression of food intake and body
Mette Q. Ludwig, Bernd Coester, Desiree Gordian, Shad Hassan, Abigail J. Tomlinson, Mouhamadoul Habib Toure, Oliver P. Christensen, Anja Moltke-Prehn, Jenny M. Brown, Dylan M. Rausch, Anika Gowda, Iris Wu, Stace Kernodle, Victoria Dong, Mike Ayensu-Mensah, Paul V. Sabatini, Jae Hoon Shin, Melissa Kirigiti, Kristoffer L. Egerod, Christelle Le Foll, Sofia Lundh, Marina Kjærgaard Gerstenberg, Thomas A. Lutz, Paul Kievit, Anna Secher, Kirsten Raun, Martin G. Myers, Tune H. Pers   +27 more
openaire   +2 more sources

Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? [PDF]

IntroductionGlucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response
Eka Melson (12122895), Dimitris Papamargaritis (7749383), Prathima Gogineni (18839104), Melanie Davies (545715)   +3 more
core  

Brain Amylin Signaling, Feeding, and Reward. [PDF]

Compr Physiol
Mietlicki-Baase EG.
europepmc   +1 more source

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. [PDF]

Hypertension
Verma S, Böttcher M, Brown P, Dicker D, Rubino D, Sbraccia P, Sharma AM, Smedegaard L, Sørrig R, Garvey WT.   +9 more
europepmc   +1 more source